Dare Bioscience, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Dare Bioscience, Inc. (DARE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -13.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-26
- Dare Bioscience, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -13.00%.
- Dare Bioscience, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -5.49%.
- Dare Bioscience, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -0.75%.
- Dare Bioscience, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -0.57%, a 239.02% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -13.00% 10-K · filed 2026-03-26 | |
| 2024-12-31 | -5.49% 10-K · filed 2026-03-26 | |
| 2023-12-31 | -0.75% 10-K · filed 2025-03-31 | |
| 2022-12-31 | -0.57% 10-K · filed 2024-03-28 | 0.57% 10-K · filed 2023-03-30 |
| 2021-12-31 | 0.41% 10-K · filed 2023-03-30 | |
| 2020-12-31 | 0.34% 10-K · filed 2022-03-31 | |
| 2019-12-31 | 0.44% 10-K · filed 2021-03-30 | -0.44% 10-K · filed 2020-03-27 |
| 2018-12-31 | -0.08% 10-K · filed 2020-03-27 | |
| 2017-12-31 | -3.40% 10-K · filed 2019-04-01 | |
| 2016-12-31 | 0.00% 10-K · filed 2018-03-28 | 0.50% 10-K · filed 2017-03-31 |
| 2015-12-31 | -0.70% 10-K/A · filed 2017-06-13 | 0.70% 10-K · filed 2016-03-10 |
| 2014-12-31 | 0.90% 10-K · filed 2016-03-10 | -0.90% 10-K · filed 2015-03-19 |
| 2013-12-31 | -1.10% 10-K · filed 2015-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |